Celgene to acquire Abraxis Bioscience for $2.9 billion up front

Celgene is to acquire Abraxis Bioscience for $2.9 billion up front in a deal aimed at boosting its oncology presenceby immediate entry into solid tumours, building on Celgene's blood cancers business.